Skip to content
Screener

Stryker SYK MedSurg and Neurotechnology: — Research, development and engineering expenses

Other segment segments

Orthopaedics
$158M—

Similar metrics at other companies

Atmus Filtration Technologies logo
ATMUIndustrial Solutions — Research, development and engineering expenses
$0—
Atmus Filtration Technologies logo
ATMUPower Solutions — Research, development and engineering expenses
$8.1M-11.0%
Hayward Holdings logo
HAYWNAM — Research, development and engineering expense
$7.25M+25.1%
Amplitech Group, Inc. logo
AMPGManufacturing And Engineering — Research And Development Expense
$503.05K-32.0%
Hayward Holdings logo
HAYWE&RW — Research, development and engineering expense
$421K+26.8%
MaxCyte logo
MXCTCell Engineering Technology — Research And Development Expense
$3.71M-29.6%

Other financials

Income statement

See full
Revenue$6.6B+9.4%
Gross profit$4.5B+17.1%
Operating income$1.7B+49.1%
Net income$1.3B+44.3%
EPS (diluted)$3.30+44.1%

Balance sheet

See full
Cash & equivalents$3.4B+42.8%
Total debt$14.2B-15.2%
Total assets$47.9B+3.5%

Cash flow

See full
Operating cash flow$1.3B+13.5%
CapEx$202.0M+10.4%
Free cash flow$1.1B+14.1%

Valuation

See full
Market cap$129.28B-9.8%
Enterprise value$140.08B-11.2%
P/E34.7×-14.5×
P/S5×-1.0×

Profitability

See full
Gross margin65%+0.8pp
Operating margin21.4%+6.2pp
Net margin14.4%+2.2pp
FCF margin18.2%+1.3pp

Returns & leverage

See full
Return on equity32.8%—
Debt / equity0.8×—
Current ratio2.2×+0.4×

Where this comes from

Reported directly by Stryker in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Stryker’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 11:10 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000310764-26-000031
Segment ResultsThree Months / 2026Three Months / 2025
MedSurg and Neurotechnology$1,291$1,175
Orthopaedics823775
Cost of sales$2,114$1,950
MedSurg and Neurotechnology$231$208
Orthopaedics146158
Segment research, development and engineering expenses$377$366
MedSurg and Neurotechnology$930$859
Orthopaedics880925

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Stryker's medsurg and neurotechnology: — research, development and engineering expenses?
Stryker (SYK) reported medsurg and neurotechnology: — research, development and engineering expenses of $231M in Q1 2026.
How has Stryker's medsurg and neurotechnology: — research, development and engineering expenses changed year-over-year?
Stryker's medsurg and neurotechnology: — research, development and engineering expenses increased by 11.1% year-over-year, from $208M to $231M.
What is the long-term trend for Stryker's medsurg and neurotechnology: — research, development and engineering expenses?
Over 3 years (2022 to 2025), Stryker's medsurg and neurotechnology: — research, development and engineering expenses has grown at a 10.9% compound annual growth rate (CAGR), from $682M to $931M.
What does medsurg and neurotechnology: — research, development and engineering expenses mean?
Includes all costs associated with the design, development, and engineering of new products and technologies within the MedSurg and Neurotechnology segment. This investment is critical for maintaining a pipeline of innovative medical devices and sustaining long-term competitive advantage. It reflects the company's commitment to technological advancement and clinical efficacy.

Ask your AI about Stryker's medsurg and neurotechnology: — research, development and engineering expenses.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude